# Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects

> **NCT02710630** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 35 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dabigatran etexilate tablet E1
- **DRUG:** Dabigatran etexilate tablet D1
- **DRUG:** Dabigatran etexilate tablet C1
- **DRUG:** Dabigatran etexilate tablet B1
- **DRUG:** Dabigatran etexilate tablet A1
- **DRUG:** Dabigatran etexilate capsule

## Key facts

- **NCT ID:** NCT02710630
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-22
- **Primary completion:** 2016-05-11
- **Final completion:** 2016-06-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02710630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02710630, "Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT02710630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*